Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen's Onions Heads to BioReliance; Millipore to Replace CFO; Gene Logic Promotes Brinkerhoff; BIO Fleshes Out Board; and Others

NEW YORK (GenomeWeb News) — BioReliance has appointed David Onions CSO, effective June 18. Onions will run the company’s global clinical and preclinical scientific activities, the company said. Onions comes to BioReliance from Invitrogen, where he was CMO.

Millipore said Kathleen Allen is leaving her post as CFO, and has selected Charles Wagner to take her position.
The company said Wagner will take over in mid-August, but Allen will remain at the company until Feb. 18, 2008, to help with the transition.    

Gene Logic has promoted V.W. Brinkerhoff to the post of senior vice president of administration. He will receive a $100,000 cash incentive bonus and a $250,000 executive cash incentive target for 2007.
Brinkerhoff joined Gene Logic in 2005 as senior vice president and general manager for its preclinical contract research business.
Prior to joining Gene Logic, he was group vice president for operations at Wilson Greatbatch Technologies. Earlier, he held senior management positions with Life Technologies, now Invitrogen.

The Biotechnology Industry Organization elected new board members this week in conjunction with its annual International Convention:  
  • Joshua Boger, chairman, president and CEO of Vertex Pharmaceuticals, was elected  chairman of the board. He succeeds James Mullen, CEO of Biogen;  
  • Joseph Scodari, worldwide chairman of Johnson & Johnson’s Pharmaceuticals group, was named vice chair of healthcare; 
  • Andrew Baum of SemBioSys Genetics was appointed vice chair of food and agriculture, and secretary; and  
  • Mark Skaletsky, chairman, president and CEO of Trine Pharmaceuticals, was named treasurer.  

ExonHit Therapeutics has appointed Deborah Smeltzer to its supervisory board.  Smeltzer is CFO and vice president of operations at Dynavax Technologies. She formerly was vice president and general manager of Applied Biosystems’ genetic-analysis business, and had been CFO and a vice president at Genset.

US Genomics has named Salvatore Salamone to its board of directors. Salamone is chairman and CEO of Saladax Biomedical. He formerly was vice president of R&D at Roche Diagnostics and was senior vice president of R&D at Orasure Technologies.

MWG Biotech has tapped Avril Hamilton for the post of UK and Ireland sales manager, and hired Krish Sakhamuru to be the key account salesperson. 

Before joining MWG, Hamilton was senior European territory manager at Cogenics and was in sales at PerkinElmer and Bio-Rad.

Sakhamuru was an account manager with Elsevier MDS and Informax.

Kary Mullis has joined the board of directors at Insight Medical Group.
Mullis is currently a distinguished researcher at Oakland’s Children’s Hospital and Research Institute.

MDS Pharma Services has hired James Pusey as vice president and general manager of its global clinical-development business.
Pusey formerly was president and CEO of OrthoLogic, executive vice president for neurology at Serono, and vice president of marketing and therapeutics area leader for AstraZeneca.

Pharsight has hired Jean-Francois Marier to the new post of vice president of reporting and analysis services.
Marier previously was director of MDS Pharma’s PK/PD department in Montreal.

Aushon BioSystems has appointed Ken Titlebaum as CFO and Mike Tognotti as vice president of worldwide sales and marketing, the company said.
Titlebaum formerly was CFO of Etex and was vice president and controller of the Kendall Company. Tognotti was formerly with CombiMatrix, Illumina, and Fisher Scientific.

Rosetta Genomics has named Michael French president of its US business. French previously was a senior vice president at Sirna, and was CBO at Entelos.

DiaDexus has appointed Chuck Patrick to its board of directors. Patrick has been president and CEO of CallNexus, and was vice president of sales and marketing for Biosite. He is currently a director at OraSure Technologies.

Martin Gollery, associate director of the Center for Bioinformatics at the University of Nevada at Reno, will return to TimeLogic as a senior bioinformatics scientist, he wrote in an e-mail to Genome Technology, a GenomeWeb Daily News sister publication.

CombiMatrix has appointed Dindyal Ramkissoon vice president of sales and marketing for its CombiMatrix Molecular Diagnostics segment.
Ramkissoon was North American sales manager at Perceptive Systems, which later became Perceptive Scientific Instruments and was acquired by Applied Imaging in 2000.

Compugen has appointed Ronit Lerner to be CFO, and has named Rachel Bart as general counsel.
Lerner formerly was CFO of Shunra Software, while Bart joins the company from Teva Pharmaceutical Industries, where she was assistant general counsel.

The Chemists' Club of New York has awarded Phillip Sharp, a professor at the Massachusetts Institute of Technology, with the club’s Winthrop-Sears Award. The award will be given on May 17 at the Chemical Heritage Foundation in Philadelphia.
Sharp is a co-discoverer of RNA splicing and he been at MIT since 1974. He is a co-founder of Biogen and is a winner of the 1993 Nobel Prize in Physiology or Medicine.

BioServe has named Kevin Krenitsky CEO. He was formerly CEO of Parkway Clinical Laboratories was senior vice president and division head at SeraCare Life Sciences’ Genomics Collaborative division.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.